Press Releases
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 –
Zymeworks Outlines Strategic Priorities and Outlook for 2026
VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key milestones for 2026. Following a year of significant clinical, operational and financial progress, Zymeworks is focused on executing a long-term strategy designed to maximize value creation for patients, partners, and shareholders...
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs...
StubHub Deadline: STUB Investors Have Opportunity to Lead StubHub Holdings, Inc. Securities Lawsuit
NEW YORK, Jan. 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of StubHub Holdings, Inc. (NYSE: STUB) pursuant and/or traceable to the Registration Statement issued in connection with StubHub's September 2025 initial public offering (the "IPO"), of the important January 23, 2026 lead plaintiff deadline. So what: If you purchased StubHub common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement...
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026...
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2025. Fourth quarter 2025 preliminary unaudited financial results For the three-month period ended December 31, 2025, as compared to the same period of 2024: Total revenue of approximately $280 million, an increase of 39% Reported approximately 79,000 oncology tests, an increase of 38% Report...
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. “2025 was a year of strong commercial execution and rapid R&D progress, setting up the company for continued growth and many important milestones in 2026,” said Reshma Ke...
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. B iologics Licensing Application (BLA) Submission for risto-cel (Previously Known as BEAM-101) Expected as Early as Year-End 2026 Expansion of Liver-targeted Genetic Disease Franchise Underway with New Program to be Announced in First Half of 2026 Ended 2025 with Estimated $1.25 Billion in Cash, Cash Equivalents and Marketable Securities; Projected Operating Runway Extension into 2029 Supports Anticipated risto-cel Launch and Execution of BEAM-302 Pivotal Development Plan CAMBRIDGE, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) today announced continued progress toward its mission to build a sustainable, predictable model for the advancement of precision genetic medicines, highlighting recent updates for its liver-targeted genetic disease and hematology franchises and strategic priorities in 2026, supported by an extended anticipated operating runway...
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
– Launched KOMZIFTI ™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the period from first commercial sale on November 21, 2025, through December 31, 2025 – – Company poised for breakthrough progress in 2026 with deep pipeline of potentially transformative therapies – SAN DIEGO, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today highlighted recent accomplishments, reported preliminary KOMZIFTI™ (ziftomenib) net product revenue and outlined anticipated 2026 milestones. “Following the landmark FDA approval of KOMZIFTI on November 13, 2025, we are executing a robust commercial launch to drive rapid adoption and market share growth,” said Troy Wilson, Ph.D...
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: RPRX), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026...
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, “Alnylam 2030,” focused on scaling the Company's operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility. Alnylam also today reported preliminary* fourth quarter and full year 2025 global net product...
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at 5:15 pm PT (8:15 pm ET) BRISBANE, Calif...
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Full Year 2025 Select, Preliminary, Unaudited Financial Results Revenue of ~$1.27 billion, representing ~83% growth year-over-year, including ~30% organic growth (excluding Ambry) Diagnostics revenue of ~$955 million, representing ~111% growth ye...
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited Financial Results For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report: Total revenue of between $138 million and $140 million, an increase of between 16% and 18% Testing revenue of...
Joint Statement Regarding Resolution of Litigation Between Aristocrat and Light & Wonder
LAS VEGAS--(BUSINESS WIRE)--Aristocrat Leisure Limited (ASX:ALL) and Light & Wonder (ASX:LNW) have agreed to settle their pending litigation in Australia and the United States which Aristocrat brought following the launch of Light & Wonder's Dragon Train game, which Aristocrat contends was developed using Aristocrat's trade secrets and copyright works. Aristocrat later made similar claims against Light & Wonder's Jewel of the Dragon game. While the specific terms of the settlement r...
Allegiant and Sun Country Airlines to Combine, Creating a Leading, More Competitive Leisure-Focused U.S. Airline
Brings Together Airlines with Similar Flexible Capacity Models Serving 22 Million Annual Customers, Nearly 175 Cities, With More Than 650 Routes, and 195 Aircraft Complementary Route Networks, Diversified Fleet, and Third-Party Travel Business Expand Choice, and Service for Passengers, Allowing Them to Reach More U.S. and International Vacation Destinations Strengthens Diversified Operations with Long-Term, Contractual Charter and Cargo Customers Strong Margins and Balance Sheet Support Growth Drive Shareholder Returns Expected to Generate $140 Million in Annual Synergies by Year 3 Post Close; Accretive to EPS Year 1 Post Closing While Enhancing Long Term Financial Returns Larger Loyalty Program Will Boost Rewards with Expanded Earning Options, Richer Benefits, and Greater Flexibility for Travelers More Opportunities for Team Members with a Shared Commitment to People and Service Committed to Maintaining Significant Presence in Minneapolis-St. Paul as an Important Base of Operations and Key Anchor City Investor Conference Call Scheduled for Monday, January 12 at 8:30 AM Eastern Time LAS VEGAS and MINNEAPOLIS, Jan. 11, 2026 /PRNewswire/ -- Allegiant (NASDAQ: ALGT) and Sun Country Airlines (NASDAQ: SNCY) today announced a definitive merger agreement under which Allegiant will acquire Sun Country in a cash and stock transaction at an implied value of $18.89 per Sun Country share. Sun Country shareholders will receive 0.1557 shares of Allegiant common stock and $4.10 in cash for each Sun Country share owned, representing a premium of 19.8% over Sun Country's closing share price of $15.77 on January 9, 2026, and 18.8% based on the 30-day volume-weighted average price...
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week data from Phase 1 trial of MBX 4291, a dual GLP-1/GIP co-agonist prodrug with potential for once-monthly dosing and improved tolerability for obesity, anticipated in Q4 2026 Nomination of two additional obesity candidates expected in 2026: an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, each designed for once-monthly dosing Strong cash position: preliminary unaudited cash, cash equivalents and marketable securities of approximately $373.7 million as of December 31, 2025, expected to fund operations into 2029 CARMEL, Ind., Jan. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced it will provide an update on its clinical programs, expanding obesity pipeline, and outlook for 2026 during the Company's presentation at the 44th Annual J.P...
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx -Melanoma, TissueCypher ) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2025. “We are extremely pleased with our excellent fourth quarter and full year preliminary results, which reflect both the strength of our innovative test portfolio and the dedication of the entire Castle team,” said Derek Maetzold, president and chief executive officer of Castle Biosciences...
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier...
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2025, as well as provided 2026 product revenue guidance and select milestones for 2026. “2025 was a remarkable year for Cerus, as patient access to INTERCEPT treated blood components increased meaningfully around the world,” said William “Obi” Greenman, Cerus' president and chief executive officer. “During 2025, based on the number of kits sold, we...
Rich Sparkle Holdings Closes Acquisition of TikTok Icon Khaby Lame's Core Company
Exclusive Global Full-Chain Operations Secured—Turning Influence into a Capital-Grade AssetWith 360 Million Followers, Annual Live-Commerce Sales Could Reach $4 Billion HONG KONG, Jan. 11, 2026 /PRNewswire/ -- Khaby Lame, widely regarded as the world's defining TikTok creator, built his name on a universal language: silence. No captions needed, no cultural footnotes required—just clarity, humor, and that unmistakable gesture that says this is the simple way...
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
New Phase I/II RGX-202 functional data demonstrates long-term, durable treatment effect at pivotal dose at 18 months Robust patient enrollment in confirmatory trial continues, expect majority of patients to be dosed by planned BLA filing, mid-year Expecting FDA PDUFA decision and multiple pivotal top-line data readouts in 2026 to support potential commercial launches 2026-2028 In-house manufacturing and strategic global partnerships driving commercial readiness Presentation at 44th Annual J.P. Morgan Healthcare Conference Wednesday, January 14 ROCKVILLE, Md...
Exagen Inc. Announces Select Preliminary 2025 Financial Results
CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced accelerated timelines for the completion of enrollment and a Phase 3 data readout from the EMPEROR...
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK net product revenue, and outlined the Company's strategic vision to drive the next stage of growth of its rare disease business...
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including an overview of key corporate objectives for 2026.
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results
PLEASANTON, Calif., Jan. 11, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2025.
Sensormatic Solutions Introduces EAS-based, Category-level Shrink Intelligence at NRF Big Show
NEUHAUSEN, Switzerland--(BUSINESS WIRE)--Sensormatic Solutions, the leading global retail solutions portfolio of Johnson Controls (NYSE: JCI), is offering retailers a new way to implement a data-driven approach to LP and organized retail crime (ORC) prevention using trusted acousto-magnetic (AM) technologies. Its Category-Level Shrink Insights ecosystem is designed to turn existing electronic article surveillance (EAS) infrastructure into an intelligent LP solution, driving operational improvem...
54% STRIDE (LRN) CRASH: Hagens Berman Scrutinizing Stride (LRN) Over Alleged "Ghost Students" Fraud and Concealed Tech Failure
LRN Investors with Losses Encouraged to Contact the Firm Before Jan. 12, 2026 Deadline in Securities Class Action San Francisco, California--(Newsfile Corp. - January 11, 2026) - National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Stride, Inc. (NYSE: LRN) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 12, 2026. The firm urges investors who suffered substantial losses in LRN to contact Hagens Berman now to discuss their rights...
Commerce Supports Universal Commerce Protocol, Plans to Offer Buying Directly Across Google's AI Surfaces
AUSTIN, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Commerce (Nasdaq: CMRC), an open, intelligent ecosystem of technology solutions and the parent company of leading ecommerce platform BigCommerce and data feed optimization leader Feedonomics, today announced its endorsement of Google's new Universal Commerce Protocol (UCP). The new, open-source standard creates a common language for agents and systems to work together across the entire shopping journey from discovery and buying to post-purchase experiences...
Walmart and Google Turn AI Discovery Into Effortless Shopping Experiences
BENTONVILLE, Ark.--(BUSINESS WIRE)--Today, Walmart Inc. and Google share plans to launch a new experience that pairs the intelligence of Google's Gemini with Walmart and Sam's Club's unmatched assortment, value and convenience, to make shopping more intuitive, reliable and perfectly aligned with the rhythms of everyday life. The new experience — built by Walmart and accessible directly within Gemini using the Universal Commerce Protocol — addresses several key customer needs: Great items, at gr...
Honeywell Unveils AI-Enabled Technology to Personalize In-store Shopping with Google Cloud
New Smart Shopping Platform, developed in collaboration with 66degrees, brings digitally enhanced personalization and navigation to the brick-and-mortar retail environment with Google's AI. NEW YORK, Jan. 11, 2026 /PRNewswire/ -- Honeywell (Nasdaq: HON) today announced the launch of an AI-enabled retail solution developed in collaboration with Google Cloud and 66degrees that leverages Google's Gemini and Google Cloud's Vertex AI platform to transform the in-store shopping experience for retailers worldwide...
Kroger Scales Generative AI Strategy with Google Cloud to Drive Digital Growth and Personalization
Kroger will use Google Cloud new agentic platform, Gemini Enterprise for Customer Experience, to simplify and transform how customers shop and eat CINCINNATI and SUNNYVALE, Calif., Jan. 11, 2026 /PRNewswire/ -- The Kroger Co. (NYSE: KR) today announced an expanded relationship with Google Cloud.
The Home Depot and Google Cloud Launch Agentic AI Tools to Help Customers and Associates Bring Projects from 'How-to' to 'Done'
Expanded partnership introduces AI agents that go beyond advice to take action—giving customers project recommendations and managing complex material orders for pros NEW YORK, Jan. 11, 2026 /PRNewswire/ -- Today at NRF 2026, The Home Depot and Google Cloud announced an expansion of their strategic partnership, further advancing the interconnected retail experience with new agentic AI tools that provide real-time, expert assistance to homeowners and professional customers (pros) like contractors, renovators and remodelers. Through the deployment of Google Cloud's AI, The Home Depot is extending its home improvement expertise from the store aisles to customers' fingertips, including new capabilities in its Magic Apron assistant, AI-powered product list builders for pros, and new tools to improve customer and store support...
Papa Johns and Google Cloud Reimagine the Future of Food Ordering to Better Serve Customers
Using Google Cloud's new agentic solution, Gemini Enterprise for Customer Experience, Papa Johns is the first restaurant to bring new omnichannel food ordering capabilities to market NEW YORK, Jan. 11, 2026 /PRNewswire/ -- Today at NRF 2026, Papa Johns announced a major transformation of its digital ordering experience, designed to deliver speed, accuracy, and real-time personalization to its 150 million+ customers worldwide. The QSR leader is the first partner for Google Cloud's newly expanded AI solution, Food Ordering agent, which is helping the pizza brand deploy a fully unified voice and text AI ordering system to remove friction across customer touchpoints...
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In addition, the company provided an update on the previously announced Chief Financial Officer transition...
Supermicro Announces Intelligent In-Store Retail Solutions in Collaboration with a Broad Range of Industry Partners
Innovative technologies enable retailers to implement intelligent stores at scale to deliver smarter, more responsive shopping experiences Industry partners to display production-ready AI solutions for loss prevention, digital twins, AI agents, customer analytics, and more SAN JOSE, Calif. and NEW YORK, Jan. 11, 2026 /PRNewswire/ -- Retail's Big Sho w -- Super Micro Computer, Inc. (SMCI), a Total IT Solution Provider for AI/ML, HPC, Cloud, Storage, and 5G/Edge, today announced collaboration with technology partners for AI-powered intelligent in-store retail solutions designed to meet increasing customer expectations with scalability, improved productivity and increased profitability...
Sensormatic Solutions Enhances Storefront Design, Supports Retail Media Efforts and Delivers Shrink Insights With Flexible Loss-prevention & Engagement Experience System (FLEX)
NEUHAUSEN, Switzerland--(BUSINESS WIRE)--Sensormatic Solutions, the leading global retail solutions portfolio of Johnson Controls (NYSE: JCI), has added a new, highly customizable and retail-media-ready electronic article surveillance (EAS) system to its portfolio. The Sensormatic Solutions Flexible Loss-prevention & Engagement Experience (FLEX) platform is designed to enhance front-of-store real estate by combining visual merchandising, digital content management tools, and a full suite of...
Xerox and Lexmark Debut Unified Retail Tech at NRF 2026
NEW YORK--(BUSINESS WIRE)--Xerox and Lexmark today unveil a unified suite of retail solutions at NRF 2026: Retail's Big Show, marking their first joint industry appearance. The newly combined company's offering signals a new era in retail technology and introduces innovations designed to help brands “See It, Show It, Support It, Scale It.” The suite of offerings from the newly combined company showcases decades of expertise at the world's largest retail trade show, running through Jan. 13 at th...
Impinj and EM Microelectronic Announce Gen2X Licensing Agreement
SEATTLE--(BUSINESS WIRE)--Impinj, Inc. (NASDAQ: PI), a leading RAIN RFID provider and Internet of Things pioneer, today announced a licensing agreement with EM Microelectronic, a semiconductor manufacturer specialized in the design and production of ultra-low power, low voltage integrated circuits (IC), to integrate Impinj Gen2X into future EM endpoint ICs. “We are committed to enabling a broader ecosystem of product and technology providers to deliver powerful solutions to an array of market s...
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint
Retailers Help Mitigate Risk with Oracle's AI-Driven Supply Chain Collaboration
New cloud solution empowers retailers to boost resilience and productivity through intelligent collaboration, compliance, and streamlined operations NEW YORK, Jan. 11, 2026 /PRNewswire/ -- NRF 2026: Retail's Big Show -- Oracle today unveiled Oracle Retail Supply Chain Collaboration. The new cloud solution enables retailers to more easily navigate an increasingly unpredictable and complex supplier landscape to enhance operational oversight, efficiency, vendor coordination, and compliance to help protect margins and customer satisfaction...
BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $BBNX--BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm.
Pharmaceutical Waste Management Market is expected to generate a revenue of USD 2631.59 Million by 2032, Globally, at 5.91% CAGR: Verified Market Research®
Verified Market Research a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the, "Pharmaceutical Waste Management Market Size and Forecast," With the pharmaceutical industry growing exponentially and regulatory pressures intensifying, this report presents an in-depth analysis of market dynamics, trends, and key players driving the future of pharmaceutical waste management. Verified Market Research a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the, "Pharmaceutical Waste Management Market Size and Forecast," With the pharmaceutical industry growing exponentially and regulatory pressures intensifying, this report presents an in-depth analysis of market dynamics, trends, and key players driving the future of pharmaceutical waste management...
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were also seen in patients with liver metastases, who often face poorer outcomes with this disease RARITAN, N.J., Jan. 10, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer...
Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. At the time of this analysis, the BRAFTOVI combination regimen with FOLFIRI and cetuximab dem...
ITGR LAWSUIT NEWS: Integer Holdings Corporation Sued for Fraud Over Weak Demand – Contact BFA Law before February 9 Deadline
NEW YORK, Jan. 10, 2026 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Integer, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/integer-holdings-corporation-class-action-lawsuit...
LRN LAWSUIT NEWS: Stride, Inc. Sued for Fraud Over Upgrade Issues – Contact BFA Law before January 12 Deadline
NEW YORK, Jan. 10, 2026 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws. If you invested in Stride, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit...
Oroco Files Prospectus Supplement in Connection with Bought Deal Public Offering
Prospectus Supplement and Base Shelf Accessible on SEDAR+ Vancouver, British Columbia--(Newsfile Corp. - January 10, 2026) - Oroco Resource Corp. (TSXV: OCO) (OTCQB: ORRCF) (the "Company" or "Oroco") announces that, in connection with its previously announced "bought deal" public offering, it has filed a prospectus supplement dated January 9, 2026 (the "Prospectus Supplement") to the Company's base shelf prospectus dated April 23, 2025 (the "Base Shelf" and together with the Prospectus Supplement, the "Prospectus"), to qualify the distribution of 52,631,600 units of the Company (the "Units") at a price of C$0.38 per Unit (the "Offering"), for approximate gross proceeds of C$20.0 million. Each Unit will be comprised of one common share of the Company (a "Common Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant")...
Pony.ai and BAIC BJEV Deepen Strategic Partnership to Accelerate Robotaxi Development and Commercialization
BEIJING, Jan. 10, 2026 /PRNewswire/ -- Pony.ai, a global leader in achieving large-scale mass production and commercialization of autonomous driving, and BAIC BJEV, the electric vehicle development and manufacturing arm of BAIC Group, today announced a comprehensive upgrade to their strategic partnership. The two companies will deepen cooperation across the autonomous driving value chain to accelerate the mass production, commercialization, and global deployment of high-level autonomous driving solutions...
Queen's Road Capital AGM Results
Hong Kong, Hong Kong--(Newsfile Corp. - January 9, 2026) - Queen's Road Capital Investment Ltd. (TSX: QRC) (the "Company", "Queen's Road Capital" or "QRC") is pleased to announce the voting results from its Annual General Meeting of Shareholders ("the "Meeting"), held on January 9, 2026 (the "AGM").
Sekur Private Data Ltd. Announces Non-Brokered Private Placement
VANCOUVER, BC / ACCESS Newswire / January 9, 2026 / Sekur Private Data Ltd. (OTCQB:SWISF)(CSE:SKUR)(FRA:GDT0) ("Sekur" or the "Company"), a leading Swiss hosted cybersecurity and privacy communications platform, is pleased to announce a non-brokered private placement to raise gross proceeds of up to CA$1,500,000 (US$1,050,000) (the "Private Placement") through the issuance of up to 30,000,000 units (each a "Unit")...
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13 th , 2026
Online Casinos That Accept PayPal 2026: High 5 Casino's PayPal Casino Solutions
Las Vegas, Nevada, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The onset of 2026 has seen High 5 Casino step up confidently by strengthening its position among online casinos that accept PayPal. As a result, High 5 Casino continues to offer players a modern payment solution that prioritizes the speed, security, and convenience of transactions, whether for purchases or redemptions...
VR Announces Further Upsize of Brokered Private Placement Led by Centurion One Capital to $2,750,000
VANCOUVER, British Columbia, Jan. 09, 2026 (GLOBE NEWSWIRE) -- VR Resources Limited (“VR” or the “Company”, TSXV: VRR) is pleased to announce a further upsize to its previously announced brokered private placement offering (the “Offering”). Pursuant to the upsize, the Company will now issue up to 17,187,500 units (the “Units) for aggregate gross proceeds of $2,750,000...
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 214,331 shares of common stock. Awards were made to seventeen new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Co...
MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an advance in its universal influenza program following the identification of a breakthrough functional constraint that persists across influenza viruses despite continual evolution. Using its patented HYFT Deep Data technology, MindWalk identified a functional pattern embedded in influenza biology that remains intact...
Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Walmart Inc. (Nasdaq: WMT), will become a component of the Nasdaq-100 Index (NDX), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month...
RecycLiCo Grants Stock Options
DELTA, British Columbia, Jan. 09, 2026 (GLOBE NEWSWIRE) -- RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”) (TSX.V: AMY | OTCQB: AMYZF | FSE: ID4), a critical minerals refining and lithium-ion battery upcycling company, announces that the Company has granted an aggregate of 3,000,000 stock options to Rob Chang, director, pursuant to the Company's omnibus equity incentive plan. The stock options have an exercise price of $0.13 per share and an expiry date of January 8, 2031...
Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)
Dallas, Texas--(Newsfile Corp. - January 9, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners initiates their coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI).
STLLR Gold Files the NI 43-101 Technical Report for the Hollinger Tailings Project Maiden Mineral Resource Estimate and Appoints Vice President, Human Resources
Toronto, Ontario--(Newsfile Corp. - January 9, 2026) - STLLR Gold Inc. (TSX: STLR) (OTCQX: STLRF) (FSE: O9D) ("STLLR" or the "Company") has filed a National Instrument NI 43-101 ("NI 43-101") technical report titled "National Instrument 43-101 Technical Report for the Hollinger Tailings Project, Timmins, Ontario" (the "Technical Report"), dated January 9, 2026 with a mineral resource effective date of November 25, 2025. A copy of the Technical Report is available on www.sedarplus.ca or on the Company's website www.stllrgold.com...
FCPT Announces Acquisition via Sale-Leaseback of a GreatWater 360 Auto Care Property for $1.2 Million
MILL VALLEY, Calif.--(BUSINESS WIRE)--Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties (“FCPT” or the “Company”), is pleased to announce the acquisition of a GreatWater 360 Auto Care property for $1.2 million via sale-leaseback. GreatWater is a Michigan-based operator of approximately 150 full-service automotive centers in the Midwest and Texas. The property is...
Edwards Comments on JenaValve Acquisition
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company's proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes that the acquisition would have been in the best interest of a large, growing and underserved group of pati...
Digi Power X Announces Entry into Settlement Agreement
This news release constitutes a "designated news release" for the purposes of the Company's amended and restated prospectus supplement dated November 18, 2025, to its short form base shelf prospectus dated May 15, 2025. MIAMI, FL / ACCESS Newswire / January 9, 2026 / Digi Power X Inc. ("Digi Power X" or the "Company") (Nasdaq:DGXX)(TSXV:DGX), an innovative energy infrastructure company, today announced that it has entered into a settlement agreement (the "Agreement") with H.C...
Coastal Financial Corporation Acquires GreenFi Brand, Expanding Strategic Flexibility
EVERETT, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Coastal Financial Corporation (Nasdaq: CCB), the holding company for Coastal Community Bank, today announced that it has acquired ownership of the GreenFi brand of climate-friendly consumer financial services products from Mission Financial Partners.
Indie Thriller Series BirdDog to Premiere at Cinemark Tinseltown Las Palmas on February 24, 2026
EL PASO, Texas--(BUSINESS WIRE)--ReDiscover Television, a 100GROUP client, and CLO Prods proudly announce the world premiere of BirdDog, a gripping new indie drama-thriller series created and written by Christine Lozano. Filmed entirely in the vibrant border city of El Paso, Texas, BirdDog stars Jessica Jimenez, Nichole Hamilton, Talia Leilani, Adam Zarowski, Russell Elleby and Xavier Felix as a ragtag crew of FBI rejects recruited into BirdDog Unit under CISA, Cybersecurity and Infrastructure...
Concerned Shareholders Respond to Recent News Release by Tuktu Resources Ltd.
Calgary, Alberta--(Newsfile Corp. - January 9, 2026) - The press release issued by Tuktu Resources Ltd. (TSXV: TUK) ("Tuktu" or the "Company") dated January 7, 2026 (the "Press Release"), in our opinion, is further evidence of the lack of understanding by the Tuktu Board of Directors (the "Board") and current management regarding the development of the assets of the Company and exploratory plays such as the upper Banff...
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update on Monday, January 12, during the 44th Annual J.P...